120 related articles for article (PubMed ID: 23355217)
21. Inhaled salbutamol and doping control: effects of dose on urine concentrations.
Sporer BC; Sheel AW; Taunton J; Rupert JL; McKenzie DC
Clin J Sport Med; 2008 May; 18(3):282-5. PubMed ID: 18469572
[TBL] [Abstract][Full Text] [Related]
22. Terbutaline: level the playing field for inhaled β
Jacobson GA; Hostrup M
Br J Sports Med; 2017 Sep; 51(18):1323-1324. PubMed ID: 27461883
[TBL] [Abstract][Full Text] [Related]
23. Urine concentrations of repetitive doses of inhaled salbutamol.
Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Int J Sports Med; 2011 Aug; 32(8):574-9. PubMed ID: 21563035
[TBL] [Abstract][Full Text] [Related]
24. The effects of inhaled formoterol on the autonomic nervous system in adolescents with asthma.
Sekerel BE; Sahiner UM; Can M; Abali G; Alehan D; Aytemir K
Ann Allergy Asthma Immunol; 2011 Sep; 107(3):266-72. PubMed ID: 21875547
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
Corren J; Mansfield LE; Pertseva T; Blahzko V; Kaiser K
Respir Med; 2013 Feb; 107(2):180-95. PubMed ID: 23273405
[TBL] [Abstract][Full Text] [Related]
26. Simple quantitation of formoterol and 11-nor-Δ(9)-tetrahydrocannabinol-9-carboxylic acid in human urine by liquid chromatography-tandem mass spectrometry in doping control.
Lee KM; Kim HJ; Son J; Park JH; Kwon OS; Lee J
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 967():8-12. PubMed ID: 25063922
[TBL] [Abstract][Full Text] [Related]
27. Determination of salbutamol and salbutamol glucuronide in human urine by means of liquid chromatography-tandem mass spectrometry.
Mareck U; Guddat S; Schwenke A; Beuck S; Geyer H; Flenker U; Elers J; Backer V; Thevis M; Schänzer W
Drug Test Anal; 2011; 3(11-12):820-7. PubMed ID: 22081503
[TBL] [Abstract][Full Text] [Related]
28. The salmeterol anomaly and the need for a urine threshold.
Jacobson GA; Hostrup M
Drug Test Anal; 2022 Jun; 14(6):997-1003. PubMed ID: 32314556
[TBL] [Abstract][Full Text] [Related]
29. An improved liquid chromatography-tandem mass spectrometric method to quantify formoterol in human urine.
He G; Lu J; Wang X; Xu Y; Wu Y; Dong Y; Shen L; He Z; Zhao J; Yuan H
J Chromatogr Sci; 2014 Sep; 52(8):848-51. PubMed ID: 24029618
[TBL] [Abstract][Full Text] [Related]
30. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers.
Weisfeld L; Shu Y; Shah TP
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma.
Mansur AH; Kaiser K
J Aerosol Med Pulm Drug Deliv; 2013 Aug; 26(4):190-9. PubMed ID: 23098325
[TBL] [Abstract][Full Text] [Related]
32. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
[TBL] [Abstract][Full Text] [Related]
33. Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
Price D; Hillyer EV
Expert Rev Respir Med; 2014 Jun; 8(3):275-91. PubMed ID: 24802285
[TBL] [Abstract][Full Text] [Related]
34. Cumulative high doses of inhaled formoterol have less systemic effects in asthmatic children 6-11 years-old than cumulative high doses of inhaled terbutaline.
Kaae R; Agertoft L; Pedersen S; Nordvall SL; Pedroletti C; Bengtsson T; Johannes-Hellberg I; Rosenborg J
Br J Clin Pharmacol; 2004 Oct; 58(4):411-8. PubMed ID: 15373934
[TBL] [Abstract][Full Text] [Related]
35. Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma.
Dissanayake S; Grothe B; Kaiser K
Respir Med; 2012 Dec; 106 Suppl 1():S20-8. PubMed ID: 23273163
[TBL] [Abstract][Full Text] [Related]
36. Ergogenic effects of inhaled beta2-agonists in non-asthmatic athletes.
Wolfarth B; Wuestenfeld JC; Kindermann W
Endocrinol Metab Clin North Am; 2010 Mar; 39(1):75-87, ix. PubMed ID: 20122451
[TBL] [Abstract][Full Text] [Related]
37. Validation of high-performance liquid chromatography assay for quantification of formoterol in urine samples after inhalation using UV detection technique.
Nadarassan DK; Chrystyn H; Clark BJ; Assi KH
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 May; 850(1-2):31-7. PubMed ID: 17126087
[TBL] [Abstract][Full Text] [Related]
38. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
39. Searching for new markers of endogenous steroid administration in athletes: "looking outside the metabolic box".
Cawley AT; Hine ER; Trout GJ; George AV; Kazlauskas R
Forensic Sci Int; 2004 Jul; 143(2-3):103-14. PubMed ID: 15240029
[TBL] [Abstract][Full Text] [Related]
40. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
